ASXL1 and acute myeloid leukemia: The almost high prevalence of ASXL1 mutations in patients with AML, along with their very low survival, demand further studies in this field and may even lead to new AMLs being divided into groups with or without ASXL1 mutations to better predict patient survival and may change the treatment protocol.